Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
PRTA - Prothena Corporation plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.00
DETAILS
HIGH:
$19.00
LOW:
$19.00
MEDIAN:
$19.00
CONSENSUS:
$19.00
UPSIDE:
93.29%
Stock News
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the first quarter of 2026 and provided business highlights.
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy.
Prothena Announces Leadership Team Updates
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Officer and Mr. Isaacs to General Counsel and Corporate Secretary. Mr. Malecek is departing in June.
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PD™ 2026.
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Prothena Corporation plc is maintained at a Hold rating due to mixed phase 2 data and long timelines for key programs. PRTA's leading assets, prasinezumab (Parkinson's disease) and coramitug (ATTR-CM), are in phase 3 trials with primary completion expected in 2029. The Bristol-Myers Squibb partnership provides up to $1.55 billion in milestones and royalties, with BMS-986446 in phase 2 for early Alzheimer's.
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade
The consensus price target hints at an 118.1% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Prothena Announces up to $100 Million Share Repurchase Plan
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced its Board has authorized a Share Repurchase Plan so it may repurchase up to $100 million of the Company's outstanding shares.
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $1.08 per share a year ago.
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights.
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.
FTRE vs. PRTA: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that it will report its fourth quarter and full year 2025 financial results on Thursday 2/19/26 with a conference call at 4:30pm ET.
All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy
Prothena (PRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Price Targets
Prothena (PRTA) Reiterated at Market Outperform by Citizens After Fireside Chat
$19.00
(was $9.31)
Stifel Nicolaus
Prothena price target raised to $19 from $11 at Citizens JMP
$19.00
(was $10.75)
Jason Butler
·
JMP Securities
Prothena Corp (PRTA) PT Raised to $19 at Citizens: Discovery Engine Successful
$19.00
(was $10.75)
Deutsche Bank
Prothena Corp (PRTA) PT Raised to $36 as Piper Sandler Remains Bullish
$36.00
(was $11.09)
Yasmeen Rahimi
·
Piper Sandler
Prothena price target raised to $36 from $15 at Piper Sandler
$36.00
(was $11.31)
UBS
Prothena price target raised to $20 from $14 at H.C. Wainwright
$20.00
(was $9.86)
H.C. Wainwright
Prothena price target lowered to $11 from $29 at Citizens JMP
$11.00
(was $8.27)
Jason Butler
·
JMP Securities
Prothena Corp (PRTA) PT Lowered to $62 at Oppenheimer
$62.00
(was $19.77)
Jay Olson
·
Oppenheimer
Prothena Corp (PRTA) PT Lowered to $24 at RBC Capital
$24.00
(was $19.68)
Kennen MacKay
·
RBC Capital
Prothena Corp (PRTA) PT Lowered to $28 at RBC Capital
$28.00
(was $23.03)
Kennen MacKay
·
RBC Capital
Cantor Fitzgerald Maintains Overweight on Prothena Corp, Raises Price Target to $98
$98.00
(was $58.98)
Cantor Fitzgerald
Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $110
$110.00
(was $59.47)
Oppenheimer
RBC Capital Maintains Outperform on Prothena Corp, Raises Price Target to $52
$52.00
(was $55.39)
RBC Capital
JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $50
$50.00
(was $25.95)
JMP Securities